Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Patient Square Capital LP

Q1 2025 · 13F-HR

Patient Square Capital LPholdings as filed

Filed 2025-05-14 · accession 0000950123-25-005195

$241.7M
Reported value
19
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
G76279101ROIVROIVANT SCIENCES LTD.$125.9M52.1%12,480,000CommonSOLE
457669307INSMINSMED INC$25.2M10.4%330,250CommonSOLE
53635D202LQDALIQUIDIA CORPORATION$22.5M9.29%1,522,452CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS, INC.$8.0M3.32%1,481,977CommonSOLE
67576A100OCULOCULAR THERAPEUTIX, INC.$6.7M2.79%920,199CommonSOLE
230031106CGEMCULLINAN THERAPEUTICS, INC.$6.7M2.75%878,897CommonSOLE
67080M103NRIXNURIX THERAPEUTICS, INC.$5.3M2.20%447,296CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS, INC.$5.2M2.17%116,362CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS, INC.$5.0M2.07%253,838CommonSOLE
80706P103SRRKSCHOLAR ROCK HOLDING CORPORATION$5.0M2.05%154,000CommonSOLE
254604101IRONDISC MEDICINE, INC.$4.1M1.70%83,000CommonSOLE
00847X104AGIOAGIOS PHARMACEUTICALS, INC.$4.1M1.69%139,732CommonSOLE
501575104KYMRKYMERA THERAPEUTICS, INC.$3.9M1.61%142,201CommonSOLE
N69605108PHVSPHARVARIS N. V.$3.9M1.59%245,496CommonSOLE
019770106ALLOALLOGENE THERAPEUTICS, INC.$3.5M1.43%2,368,186CommonSOLE
09627Y1092655787DBLUEPRINT MEDICINES CORPORATION$3.4M1.41%38,500CommonSOLE
45826J105NTLAINTELLIA THERAPEUTICS, INC.$1.7M0.68%232,781CommonSOLE
834203309SLNOSOLENO THERAPEUTICS, INC.$1.3M0.55%18,600CommonSOLE
92941V308VYNEVYNE THERAPEUTICS INC.$406,1120.17%257,033CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.